ALTEOGEN Inc (196170) - Total Liabilities
Based on the latest financial reports, ALTEOGEN Inc (196170) has total liabilities worth ₩261.55 Billion KRW (≈ $177.25 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore ALTEOGEN Inc operating cash flow efficiency to assess how effectively this company generates cash.
ALTEOGEN Inc - Total Liabilities Trend (2014–2024)
This chart illustrates how ALTEOGEN Inc's total liabilities have evolved over time, based on quarterly financial data. Check 196170 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
ALTEOGEN Inc Competitors by Total Liabilities
The table below lists competitors of ALTEOGEN Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Argen-X
LSE:0QW0
|
UK | €679.80 Million |
|
Investment AB Latour (publ)
ST:LATO-B
|
Sweden | Skr27.54 Billion |
|
mBank SA
WAR:MBK
|
Poland | zł258.84 Billion |
|
Juniper Networks Inc
NYSE:JNPR
|
USA | $5.26 Billion |
|
Shengyi Electronics Co. Ltd. A
SHG:688183
|
China | CN¥4.46 Billion |
|
Ovintiv Inc
NYSE:OVV
|
USA | $9.15 Billion |
|
Focus Media Information Technology Co Ltd
SHE:002027
|
China | CN¥6.96 Billion |
|
Bharat Heavy Electricals Limited
NSE:BHEL
|
India | Rs475.72 Billion |
Liability Composition Analysis (2014–2024)
This chart breaks down ALTEOGEN Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ALTEOGEN Inc (196170) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.72 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.70 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ALTEOGEN Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ALTEOGEN Inc (2014–2024)
The table below shows the annual total liabilities of ALTEOGEN Inc from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩134.92 Billion ≈ $91.43 Million |
+24.63% |
| 2023-12-31 | ₩108.26 Billion ≈ $73.37 Million |
+11.92% |
| 2022-12-31 | ₩96.73 Billion ≈ $65.55 Million |
-21.74% |
| 2021-12-31 | ₩123.61 Billion ≈ $83.77 Million |
+340.77% |
| 2020-12-31 | ₩28.04 Billion ≈ $19.00 Million |
+75.31% |
| 2019-12-31 | ₩16.00 Billion ≈ $10.84 Million |
+236.41% |
| 2018-12-31 | ₩4.76 Billion ≈ $3.22 Million |
+50.08% |
| 2017-12-31 | ₩3.17 Billion ≈ $2.15 Million |
+16.44% |
| 2016-12-31 | ₩2.72 Billion ≈ $1.84 Million |
+226.01% |
| 2015-12-31 | ₩834.62 Million ≈ $565.61K |
-60.88% |
| 2014-12-31 | ₩2.13 Billion ≈ $1.45 Million |
-- |
About ALTEOGEN Inc
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the d… Read more